IGHE and anaphylaxis: Ironically, the agent most commonly reported to trigger anaphylaxis is the anti-IgE mAb omalizumab38; however, systematic reporting and analysis of cofactors related to mAb-related anaphylaxis (aside from cetuximab) are currently lacking.